She Leads Biotech

What happens when a biotech company realises that its next stage of growth requires a completely different approach? In this episode of She Leads Biotech , I'm joined by Beverley Carr, Chief Business and Operating Officer at CHARM Therapeutics , to explore the realities of transforming promising science into a clinical-stage business. Beverley shares the decisions behind CHARM's shift from a broad AI drug discovery platform to a focused oncology programme, the challenges of restructuring a business for its next stage, and why having the right people in place matters just as much as having great science. We also discuss the real value of AI in drug discovery, the importance of making difficult decisions early, and Beverley's own journey from chemistry to biotech leadership. It's a conversation about adaptability, courage and recognising when the path forward requires doing things differently. Because sometimes the most important leadership decision isn't what to pursue next, but what you're prepared to leave behind. 🎧 Listen now on She Leads Biotech . #SheLeadsBiotech #BiotechLeadership #WomenInBiotech #DrugDiscovery #LifeSciences

How much do we really understand about our own health, and how often have we been told that symptoms are simply "normal"? In this episode, I'm joined by Paula Soteropoulos , biotech executive and investor, and her daughter Dr. Alexia Soteropoulos , an integrative and functional medicine physician, to discuss their book Restoring Balance and why women need to take a more active role in understanding their bodies. We explore the gaps in women's health research, menopause, hormone health, whole-person care and the importance of questioning symptoms that are too often dismissed or normalised. Paula brings her perspective from biotech leadership and investment, while Alexia shares her clinical approach to helping women become better informed advocates for their own health. A warm, thought-provoking conversation about knowledge, self-advocacy and restoring balance to women's healthcare.

What if the biggest challenge in biotech isn't innovation, but adoption ? I'm joined by Holley Miller, CEO of Grey Matter Marketing , to explore why better science doesn't automatically win. We talk about why people buy outcomes rather than products, why emotion can open the door before data earns belief, the importance of solving an urgent problem, and why being different can sometimes matter more than simply being better. Holley also shares her own entrepreneurial and leadership journey, the value of non-obvious thinking, taking career risks and giving yourself permission to fail. A thought-provoking conversation about innovation, human behaviour and what it really takes to turn a great idea into something people will actually adopt.

Amy Walker didn't set out to become a CEO. In this episode of She Leads Biotech, I’m joined by Amy, CEO of 4basebio , to explore how a career that began in science evolved into leading a growing biotech company. We talk about growing alongside a business, stepping beyond your original expertise, building the right leadership team and culture, and the technology changing the future of DNA manufacturing and advanced therapies . It’s a conversation about science, leadership, career progression and being willing to take opportunities you never originally planned for. #SheLeadsBiotech #Biotech #WomenInBiotech #BiotechLeadership #DNAManufacturing #AdvancedTherapies

What happens when you reach one of the most senior positions in global drug discovery — and decide the next step is to leave the security of Big Pharma behind? In this episode of She Leads Biotech, I’m joined by Karin Conde-Knape, PhD, Chief Science Officer at Valo Health , whose international career has taken her through leadership roles at Roche, Johnson & Johnson and Novo Nordisk. We talk about why Karin believes better drug discovery needs to start with human data , how asking the right questions earlier can prevent years of time and investment being committed to the wrong path, and where data, experience and intuition belong in scientific decision-making. We also explore Karin’s decision to move from Big Pharma to biotech — what she describes as an “easier choice, not a comfortable choice” — and why impact, people and purpose became increasingly important at this stage of her career. Our conversation moves beyond the science into leadership: creating psychological safety, challenging the thought process rather than the individual , developing resilient future leaders, embracing AI and new technologies, and building teams that genuinely want to follow you. A fascinating conversation about drug discovery, human data, innovation, career courage and the leadership required to turn better questions into better science.

What does it really take to lead a biotech company when the science is complex, the stakes are high and the answers aren’t always obvious? In this episode of She Leads Biotech , I’m joined by Iris Grossman, PhD, CEO of Zelig Therapeutics , for a candid conversation about the realities of biotech leadership and her journey from scientist to CEO. In When Leadership Gets Real: Ego, Accountability & the Decisions That Shape Biotech Companies , we talk about what happens when leadership moves beyond the title and you become the person ultimately accountable for the decisions. We explore why great leaders surround themselves with people who will challenge them, how founders and leadership teams need to evolve as companies grow, why strategy starts with knowing your values, and what Iris has learned about hiring beyond technical capability. Iris also talks openly about making decisions without perfect information, handling difficult performance conversations, keeping ego out of leadership — and why patient impact remains her North Star. Chapters 00:00 Introduction 03:17 A Patient-Centric North Star 05:46 The Scientist Inside the CEO 07:04 Turning Science into Patient Impact 10:14 The Reality of CEO Accountability 13:30 When Founders and Companies Need to Evolve 14:39 Why Independent Boards Matter 15:43 Strategy Starts with Values 17:17 Why Zelig Became a Call to Action 20:01 Making Decisions Through Uncertainty 23:28 Why Personality Matters in Hiring 26:24 The Difficult People Decisions Leaders Must Make 30:09 Why Biotech Is Ultimately About People 🎧 Follow She Leads Biotech for more conversations with the people building, leading and shaping biotech. #SheLeadsBiotech #BiotechLeadership #Biotech #LifeSciences #WomenInBiotech #Leadership

What happens when the career plan you thought you had suddenly changes? In this episode of She Leads Biotech , I’m joined once again by Priya Baraniak, PhD, Chief Commercial & Development Officer at Pluristyx , who returns to the podcast after first joining me back in Season 1. In When the Plan Changes: Resilience, Reinvention & Finding Your Way in Biotech , we talk candidly about unexpected career change, resilience and what happens when you have to let go of the plan and find a different way forward. Priya shares what she learned following a professional setback, why personal branding and authentic relationships became so important, and how her own career has evolved from scientist to commercial biotech leader. We also explore the realities of biotech fundraising, what investors look for in leadership teams, the potential of iPSC technology and cell and gene therapy — and why, despite the challenges facing our industry, Priya remains incredibly excited about what the science can achieve for patients. Above all, it’s a conversation about becoming more comfortable with uncertainty, focusing on what you can control and continuing to do the next right thing. Chapters 01:23 When Everything Changes 05:25 Losing a Role: The First 72 Hours 10:05 Personal Branding & Getting Comfortable Being Visible 14:50 The Promise of iPSCs 18:00 From Scientist to Commercial Leader 21:31 What Fundraising Really Looks Like Today 23:29 Changing the Conversation About Inclusion 28:28 Why Cell & Gene Therapy Still Excites Her 31:28 What 13-Year-Old Priya Would Think Today 35:27 Just Keep Doing the Next Right Thing 37:02 Tough Times Didn't Break Us, They Made Us 🎧 Follow She Leads Biotech for more conversations with the people building, leading and shaping biotech. #SheLeadsBiotech #Biotech #BiotechLeadership #CellAndGeneTherapy #WomenInBiotech #LifeSciences #BiotechCareers

Reimagining Rare Disease Drug Development with Nerissa Kreher In this episode of She Leads Biotech , I’m joined by Nerissa Kreher, Chief Medical Officer of Alltrna, for a conversation about rare disease innovation, precision medicine, and the future of drug development. With more than 20 years of experience in rare diseases, Nerissa shares her journey from pediatric endocrinologist to biotech executive and explains how Alltrna is taking a novel approach to treating genetic diseases through mutation-defined therapies. A fascinating discussion about science, innovation, leadership, and hope for families living with rare diseases. Chapters 00:00 Introduction 02:00 From Medicine to Biotech 05:00 Falling in Love with Rare Disease Research 08:00 Understanding Rare Disease Communities 12:00 The Challenge of Clinical Trials in Rare Diseases 16:00 Mutation-Defined Therapies Explained 21:00 How Alltrna Is Rethinking Drug Development 26:00 Regulatory & Clinical Development Challenges 31:00 Public vs Private Company Leadership 35:00 What Makes a Great Biotech Executive 39:00 Leadership, Mentorship & Authenticity 43:00 The Role of Patients in Drug Development 47:00 The Future of Rare Disease Innovation 51:00 Bringing Hope to Patients & Families #SheLeadsBiotech #RareDisease #PrecisionMedicine #GeneTherapy #BiotechLeadership #WomenInBiotech #CNAUSAExecutiveSearch

Leading with Purpose in Rare Disease with Sarah DiSalvatore In this episode of She Leads Biotech , I’m joined by Sarah DiSalvatore, Fractional SVP of Clinical Operations & Biotech Executive, for a conversation about leadership, rare disease, and the realities of bringing innovative therapies to patients. Sarah shares her journey from bench research to executive leadership, why quality and compliance are fundamental to successful clinical development, and how fractional leadership is helping early-stage biotech companies build smarter and more efficiently. We also discuss the deeply personal experience of becoming a rare disease parent, and how that has transformed the way Sarah approaches patient advocacy, programme development, and the importance of building centres of excellence for underserved communities. A thoughtful conversation about resilience, strategy, and keeping patients at the centre of every decision. Chapters 00:00 Introduction 02:00 A Childhood Dream of Medicine 06:00 From Bench Research to Clinical Operations 11:00 Why Quality and Compliance Matter 16:00 Growing into Leadership 20:00 The Rise of Fractional Executives 25:00 Becoming a Rare Disease Parent 30:00 How Personal Experience Changed Clinical Development 34:00 Building Centres of Excellence for Rare Diseases 38:00 The Future of Clinical Operations 42:00 Advice for Parents, Caregivers & Leaders #SheLeadsBiotech #RareDisease #ClinicalOperations #BiotechLeadership #GeneTherapy #WomenInBiotech #CNAUSAExecutiveSearch

Beyond Burnout: Rethinking Leadership and Identity with Melody Keel In this episode of She Leads Biotech , I’m joined by Melody Keel, CEO of The Research Associate Group, for a candid conversation about clinical operations, leadership, burnout, and building a life beyond your job title. With more than 20 years of experience in clinical operations, Melody shares what she’s learned about leading teams, navigating high-pressure environments, and why empathy is one of the most powerful tools a leader can have. We also discuss the changing biotech job market, the importance of personal branding, and why your career should never become your entire identity. Whether you work in clinical operations or any area of life sciences, this episode is packed with practical insights and honest reflections. Chapters 00:00 Introduction 02:10 Falling into Clinical Operations 05:00 Why Great Leaders Put People First 09:30 The Reality of Burnout in ClinOps 14:00 Sponsor vs CRO Life 17:20 A Personal Wake-Up Call 20:00 Building a Life Beyond Work 23:00 The Future of Careers in Biotech 27:00 Why Your Personal Brand Matters 30:00 Supporting Women Through Career Change 33:00 Finding Your Purpose Beyond Your Job #SheLeadsBiotech #ClinicalOperations #Leadership #WomenInBiotech #CareerGrowth #LifeSciences #CNAUSAExecutiveSearch

Building Your Own Table with Jennifer Daily In this episode of She Leads Biotech, I’m joined by Jennifer Daily, neuroscientist, biotech executive, and founder, for a conversation about leadership, drug development, and the journey from employee to entrepreneur. Jennifer shares how working across clinical development, regulatory affairs, manufacturing, and preclinical research gave her a unique perspective on what it really takes to move therapies from concept to patient. We also discuss the realities of gene therapy, why execution is often more important than great science alone, the power of building a strong network, and what inspired her to launch her own company in the neuroscience space. A thoughtful conversation about leadership, risk-taking, and creating opportunities instead of waiting for them. Chapters 00:00 Introduction 02:30 Discovering Science & Neuroscience 05:00 Moving from Academia to Industry 08:00 What Industry Looks for in Scientists 10:00 Seeing the Full Drug Development Picture 13:00 Why Great Science Isn't Enough 16:00 Funding Plans, Not Hope 19:00 From Executive to Founder 22:00 Building a Company in Neuroscience 25:00 Creating a Culture Where Every Voice Matters 28:00 Risk, Decision-Making & Leadership 31:00 The Future of Gene Therapy 34:00 Career Advice, Networking & Growth #SheLeadsBiotech #WomenInBiotech #BiotechLeadership #GeneTherapy #Neuroscience #FemaleFounder #CNAUSAExecutiveSearch

Rethinking IVF with Ivana Muncie-Vasic In this episode of She Leads Biotech, we’re joined by Ivana Muncie-Vasic, CEO & Founder of Vitra Labs, for a conversation about fertility innovation, bioengineering, and building a biotech company from the ground up. Ivana shares how her work in stem cell biology led to the development of hormone-free IVF technology designed to reduce the physical and financial burden of fertility treatment for patients. We also talk about the realities of becoming a first-time founder, navigating imposter syndrome, building resilience as a CEO, and how becoming a new mother has deepened her connection to the mission behind Vitra Labs. Chapters 00:00 Introduction 02:00 Finding Bioengineering & Stem Cell Research 07:00 Why Patient Impact Became the Focus 10:00 From Academic Research to Founding Vitra Labs 14:00 The Science Behind Hormone-Free IVF 19:00 Why Traditional IVF Is So Difficult on Women 23:00 Becoming a First-Time CEO 27:00 Panic Attacks, Pressure & Founder Reality 31:00 The Importance of Support & Coaching 34:00 Becoming a Mother While Building a Startup 37:00 Advice for Future Founders #SheLeadsBiotech #WomensHealth #FertilityInnovation #IVF #WomenInBiotech #CNAUSAExecutiveSearch

Changing the Conversation Around Women’s Health with Saundra Pelletier & Mitch Rosen In this episode of She Leads Biotech, we’re joined by Saundra Pelletier and Mitch Rosen from Evofem Biosciences for a candid conversation about women’s health, education, intimacy, and the importance of normalizing these discussions. We explore why women deserve more options, why men need to be part of the conversation too, and how a new generation is changing the way people think about sexual health and communication. From access and advocacy to stigma, healthcare gaps, and the power of education, this episode is honest, insightful, and surprisingly fun. Chapters 00:00 Introduction 03:00 Evofem, Phexxi & Women’s Choice 07:00 The “Say Vagina” Campaign 12:00 Why Men Need to Join the Conversation 16:00 How Mitch Found Women’s Health 21:00 What’s Changing in Women’s Healthcare 26:00 Shared Responsibility & Communication 31:00 Generational Shifts Around Intimacy 35:00 Myths & Misconceptions in Women’s Health 40:00 AI, Access & The Future of Care 45:00 What Real Progress Looks Like 49:00 Final Advice & Takeaways #SheLeadsBiotech #WomensHealth #HealthcareInnovation #WomenInBiotech #CNAUSAExecutiveSearch

Trusting Your Judgement in Biotech with Anna Polak-Andersen In this episode of She Leads Biotech, we’re joined by Anna Polak-Andersen, CEO of AnRes Clinical, for a thoughtful conversation about clinical development, leadership, and navigating the biotech industry across Europe. Anna shares her journey from studying pharmacy in Poland to leading a clinical development consultancy supporting biotech companies and rare disease programs across the industry. We talk about the realities of clinical research, the importance of strategic thinking in development, the current European biotech landscape, and why learning to trust your own judgement is one of the most important leadership lessons of all. Chapters 00:00 Introduction 03:00 Why Anna Chose Clinical Development 08:00 Early Career at Pfizer 11:00 Staying Connected to Patient Impact 15:00 What Makes AnRes Clinical Different 20:00 Choosing the Right Clients & Partnerships 24:00 European Biotech & Funding Challenges 28:00 Women in Leadership & Self-Doubt 32:00 Trusting Your Own Judgement 35:00 Advice for the Next Generation #SheLeadsBiotech #ClinicalDevelopment #WomenInBiotech #BiotechLeadership #CNAUSAExecutiveSearch

Building a biotech company takes more than science. In this episode of She Leads Biotech , Dr. Stella Vnook, CEO of Aviva Ventures, shares her journey from arriving in the US with nothing to leading multiple biotech ventures and supporting the next generation of founders. We explore the realities of building in biotech, from self-doubt and uncertainty to navigating the business side of science, and why so many great ideas never get started. A practical and honest conversation about resilience, leadership, and what it really takes to turn science into impact. Chapters 00:00 Introduction 01:30 Stella’s Early Journey 05:00 Building a Career in Life Sciences 09:00 Self-Doubt and Leadership 13:00 From Pharma to Entrepreneurship 18:00 Starting Without Knowing How 23:00 Common Mistakes Founders Make 27:00 Building Multiple Companies 32:00 The Story Behind Caerra 36:00 Aviva Ventures and Supporting Founders 40:00 Advice for Early-Stage Founders 44:00 What Success Looks Like #SheLeadsBiotech #WomenInBiotech #BiotechLeadership #LifeSciences #CNAUSAExecutiveSearch

Solving More Than Science with Adrienne Mendoza Cell and gene therapy is advancing rapidly, but science alone isn’t enough. In this episode of She Leads Biotech , Adrienne Mendoza, Chief Operating Officer of BBG Advanced Therapies, shares what’s really needed to move the field forward, from improving access and infrastructure to rethinking how these therapies reach patients. We also explore her journey over the past year, building a stronger presence in the industry, translating complex science for broader audiences, and the realities of leading through a challenging and evolving market. A practical and honest look at where the field is today, and what it will take to get to the next stage. Chapters 00:00 Introduction 02:00 Stepping into a New Role at BBG Advanced Therapies 05:00 How the Role of a COO Evolves 08:30 Building Presence and Community in CGT 12:00 Making Complex Science Understandable 16:00 The Mobile Leukapheresis Bus 21:00 Access Challenges in Cell & Gene Therapy 27:00 What Needs to Change in the System 33:00 Industry Challenges and Optimism 38:00 What the Next 5 Years Could Look Like 41:00 Life Outside of Biotech #SheLeadsBiotech #CellAndGeneTherapy #BiotechLeadership #LifeSciences #CNAUSAExecutiveSearch

Rethinking Eye Care: From NanoDropper to Mu Medical What started as a student project has turned into a company reshaping how eye care is delivered. In this episode of She Leads Biotech , we’re joined by Allisa Song, CEO of Mu Medical, and Mackenzie Andrews, CCO, to talk about the journey from an idea sparked in a research lab to a product now used across thousands of clinics. They share how a simple question, why are eye drops too big, led to a solution that improves patient outcomes, reduces waste, and is now evolving into something much bigger. We also get into co-founder dynamics, building in a complex healthcare system, and the reality of being young female leaders in a traditionally male-dominated space. A practical, honest conversation about building, scaling, and challenging assumptions in healthcare. Chapters 00:00 Introduction 01:30 Meet Allisa & Mackenzie 04:00 From Research Lab to Startup Idea 08:30 The Eye Drop Problem Explained 13:00 Building NanoDropper 18:30 When It Became a Real Business 22:00 Product Demo & Clinical Impact 26:00 Go-to-Market Strategy 30:00 Working with Insurers, Clinics & Pharma 34:00 Evolving into Mu Medical 38:00 Co-Founder Dynamics & Trust 42:00 Being Women in a Male-Dominated Industry 47:00 Advice for Founders 51:00 What’s Next for Mu Medical Listen / Watch: Spotify | YouTube #SheLeadsBiotech #MedTech #HealthcareInnovation #WomenInBiotech #CNAUSAExecutiveSearch

Finding Your Path in Biotech with Connie Chang Careers in biotech rarely follow a straight line. In this episode of She Leads Biotech , we speak with Connie Chang, Chief Operating Officer of ONL Therapeutics, about a career that has spanned big pharma, academia, and emerging biotech, and how each step has shaped the way she leads today. Connie shares how early career decisions don’t always define where you end up, and why sometimes “the career picks you” rather than the other way around. We explore the reality of moving between very different environments, from highly structured global organizations to small, fast-moving biotech companies, and what it really takes to adapt and succeed in both. This conversation also highlights the importance of community throughout your career, the role academia plays in driving innovation, and the personal side of leadership, including navigating family decisions, career risks, and the pressure many women face as they progress into senior roles. A thoughtful and honest discussion on building a career, leading with intention, and continuing to grow, even when you’re already at the top. Chapters 00:00 Introduction 01:30 How Connie Found Biotech 04:00 Harvard, Community, and Early Influences 06:30 Big Pharma, Academia, and Connecting the Dots 10:00 Taking Career Risks and Moving to Michigan 14:30 ONL Therapeutics and the Mission Behind the Science 18:00 What a COO Role Really Looks Like in Biotech 20:30 Building Teams in Small Biotech 23:00 Leadership Style and Creating Trust 26:00 Adapting Across Cultures and Environments 29:00 Women in Leadership and Career Progression 32:00 Being the Only One at the Table 35:00 Self-Doubt, Growth, and Resilience 37:30 What’s Next for ONL and Connie #SheLeadsBiotech #BiotechLeadership #WomenInBiotech #LifeSciences #CNAUSAExecutiveSearch

Leading Women’s Health Innovation: From Clinical Practice to CEO with Mandy Pulliam In this episode of She Leads Biotech, I’m joined by Samantha (Mandy) Pulliam, CEO and Chief Medical Officer at Axena Health, for a conversation that highlights what it really takes to lead in women’s health. Mandy’s journey is a unique one. She started her career as a practicing physician before stepping into the biotech and medtech space, bringing with her a deep understanding of patient care that continues to shape how she leads today. What stood out to me in this conversation is how intentional she has been about bridging clinical insight with innovation. At Axena Health, she’s focused on addressing conditions that have historically been under-discussed and underserved, particularly in pelvic health. We talk about the realities of building and leading in women’s health, where the need is significant, but awareness, funding, and attention have often lagged behind. Mandy shares how she approaches leadership as both a clinician and a CEO, how she thinks about patient impact alongside commercial success, and why creating solutions in this space requires both persistence and a willingness to challenge long-standing assumptions. This is a conversation about leadership, purpose, and the responsibility that comes with developing products that directly impact patients’ quality of life. And a reminder that innovation in healthcare isn’t just about new technology, it’s about truly understanding the people you’re trying to help. 📌 Chapters 00:00 Introduction 01:48 Mandy’s journey from physician to CEO 03:52 Moving from clinical practice into industry 05:41 Why women’s health remains underserved 07:32 The mission behind Axena Health 09:18 Addressing pelvic health challenges 11:05 Bridging patient care and innovation 13:12 Leadership as both a clinician and executive 15:20 Navigating funding and awareness gaps 17:08 Building solutions that truly serve patients 19:06 Commercial strategy in women’s health 21:14 Lessons learned stepping into the CEO role 23:02 Advice for women entering biotech leadership 24:40 Balancing purpose with business outcomes 26:18 The future of women’s health innovation 🎙️ She Leads Biotech celebrates the journeys of women shaping the future of life sciences. Subscribe for more conversations with biotech leaders, founders, and innovators. #SheLeadsBiotech #WomensHealth #BiotechLeadership #LifeSciences #MedTech #WomenInBiotech #HealthcareInnovation #CNAUSAExecutiveSearch

Rethinking Rare Disease: A New Model for Ultra-Rare Therapies with Beth White In this episode of She Leads Biotech , I’m joined by Elizabeth (Beth) White, COO and Co-Founder of Orphan Therapeutics Accelerator , for a conversation that really stayed with me. Beth has spent her career at the intersection of science, strategy, and commercialization, and today she’s focused on one of the biggest challenges in our industry: how do we bring therapies to patients with ultra-rare diseases when the traditional biotech model simply doesn’t support them? As Beth explains, the science has moved forward, especially in gene and cell therapies, but the business model hasn’t kept up. And that’s leaving too many promising therapies sitting on the shelf, never reaching the patients who need them. What she and her team are building with the Orphan Therapeutics Accelerator is a completely different approach. A nonprofit biotech model designed to rethink how therapies are funded, developed, and ultimately delivered to patients. We talk about what that actually looks like in practice, from new ways of funding and partnering, to the creation of the CGT Exchange, a marketplace designed to unlock shelved assets and give them a path forward. This is one of those conversations that really challenges how you think about drug development, investment, and impact. And a reminder that behind every “ultra-rare” disease are real patients, real families, and a very real urgency to find solutions. 📌 Chapters 00:00 Introduction 01:52 Why ultra-rare diseases remain underserved 03:44 What the Orphan Therapeutics Accelerator is 05:00 Building a completely new development model 06:32 How the nonprofit structure works in practice 08:39 Creating awareness and industry engagement 10:34 Major partnerships and recent momentum 11:39 What the CGT Exchange is and why it matters 13:26 Can this model work at scale? 15:08 Beth’s journey into rare disease and gene therapy 17:01 Bridging science and business 19:18 Leadership across pharma, biotech, and nonprofit 21:19 Big pharma vs biotech mindset 23:09 Leading with limited resources 24:21 Advice for women in biotech 25:37 Risk-taking and career decisions 26:17 The future of rare disease development 28:40 The role of AI in accelerating progress 🎙️ She Leads Biotech celebrates the journeys of women shaping the future of life sciences. Subscribe for more conversations with biotech leaders, founders, and innovators. #SheLeadsBiotech #BethWhite #RareDisease #GeneTherapy #BiotechInnovation #WomenInBiotech #LifeSciences #CNAUSAExecutiveSearch